The Study of a Novel Triple Spray Combination of Corticosteroid, Antihistamine and Decongestant Delivered in a Single Spray

Allergy rhinitis (AR) is a chronic condition that affects quality of life of many individuals. We hypothesized that a novel triple spray combination would provide better symptom relief for patients with AR compared to the use of a single nasal spray. Triple spray is a mixture of triamcinolone, azelastine, and eight sprays of oxymetazoline combined in one bottle. We administered an institutional review board approved questionnaire to patients with AR age 18 and above currently on any types of nasal sprays. Out of 97 patients, 67 used a single nasal spray (either an antihistamine or a corticosteroid spray), and 30 used the triple spray combination. There is no difference (p = 0.134) in the total symptom relief score between the use of one nasal spray versus triple spray. However, the triple spray provided a statistically significant difference in the scores rating sinus pressure relief (p = 0.039) compared a single nasal spray. There was no statistical difference (p = 0.687) in the severity of symptoms between the two groups. The triple spray decreases AR symptoms by decreasing inflammation and mast cell activities with an addition of the vasoconstrictive property of oxymetazoline. Our preliminary data suggests that the triple spray is an effective AR treatment that offers a statistically significant improvement in management of sinus pressure compared to a single nasal spray.